Immunome, Inc. $IMNM Shares Acquired by TD Asset Management Inc

TD Asset Management Inc grew its position in Immunome, Inc. (NASDAQ:IMNM) by 8.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 759,192 shares of the company’s stock after acquiring an additional 57,912 shares during the period. TD Asset Management Inc’s holdings in Immunome were worth $16,307,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after acquiring an additional 1,144,788 shares during the period. Geode Capital Management LLC raised its position in shares of Immunome by 24.6% during the 4th quarter. Geode Capital Management LLC now owns 2,361,381 shares of the company’s stock worth $50,731,000 after purchasing an additional 466,806 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Immunome by 222.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after purchasing an additional 762,147 shares during the last quarter. Polar Capital Holdings Plc raised its position in shares of Immunome by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,058,776 shares of the company’s stock worth $12,398,000 after purchasing an additional 58,776 shares during the last quarter. Finally, Candriam S.C.A. raised its position in shares of Immunome by 170.2% during the 3rd quarter. Candriam S.C.A. now owns 859,527 shares of the company’s stock worth $10,065,000 after purchasing an additional 541,441 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Price Performance

Immunome stock opened at $18.61 on Tuesday. The firm has a 50 day simple moving average of $21.97 and a 200-day simple moving average of $21.70. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -7.82 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. Equities analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Barclays assumed coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. Craig Hallum upped their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Finally, Truist Financial upped their price objective on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Insider Activity

In related news, insider Jack Higgins sold 9,438 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the transaction, the insider owned 22,000 shares of the company’s stock, valued at approximately $476,080. This trade represents a 30.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 28,200 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $20.65, for a total transaction of $582,330.00. Following the transaction, the director directly owned 341,147 shares of the company’s stock, valued at $7,044,685.55. The trade was a 7.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 139,438 shares of company stock worth $2,964,664. Corporate insiders own 7.21% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.